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Abstract
A simple, rapid, and robust stability-indicating RP-HPLC method has been developed and validated to measure cefixime and
dicloxacillin at a single wavelength (225 nm) in order to assay. The samples were isocratically eluted using a Capcell Pak C18
DDS5 column (4.6 mm ×  250 mm with a particle size of 5 m) with a mobile phase consisting of 5 mM phosphate buffer (with a
pH adjusted to 5.4 using orthophosphoric acid): acetonitrile:methanol (42:55:03, v/v/v) delivered at a flow rate 1.0 mL min−1. A
good linear response was obtained in the range from 0.5 to 25 g mL−1. The LODs for CFX and CLX were found to be 0.020
and 0.018 g mL−1, respectively, and the LOQs for CFX and CLX were 0.315 and 0.205 g mL−1, respectively. The method was
quantitatively evaluated in terms of linearity, precision, accuracy (recovery), selectivity and robustness in accordance with standard
guidelines. The method is simple, convenient and suitable for analysing cefixime and dicloxacillin in bulk and in pharmaceutical
formulations.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
lidationKeywords: RP-HPLC stability indication; Cefixime; Dicloxacillin; Va
∗ Corresponding author at: Department of Pharmaceutical Chem-
istry, Rajarambapu College of Pharmacy, Kasegaon, Tal-Walwa, Dist
– Sangli 415404, Maharashtra, India. Tel.: +91 2342 238200;
mobile: +91 86000 09705.
E-mail address: somu1245@yahoo.co.in (S.D. Bhinge).
Peer review under responsibility of Taibah University.
http://dx.doi.org/10.1016/j.jtusci.2015.10.011
1658-3655 © 2015 The Authors. Production and hosting by Elsevier B.V. on 
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1.  Introduction
Chemically, cefixime (CFX) is (6R,7R)-7-[[2-(2-
amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)
acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo
[4.2.0]oct-2-ene-2-carboxylic acid, as shown in Fig. 1a.
It provides broad and potent activity against various
pathogens, especially gram-negative organisms, when
given orally to treat susceptible infections such asbehalf of Taibah University. This is an open access article under the
gonorrhoea, otitis media, pharyngitis, lower respiratory
tract infections and urinary tract infections [1,2].
Dicloxacillin (DLX), (2S,5R,6R)-6-[[3-(2,6-dichloro
phenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,
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-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-
arboxylic acid, is shown in Fig. 1b. It is used to treat
nfections caused by susceptible gram-positive bacteria
3]. Combination therapy is one choice for treating
arious bacterial infections.
A survey of the literature revealed that several ana-
ytical methods for analysing CFX and DLX as single
omponents or in combination with other drugs (as
ormulations and in biological samples) have been
escribed. However, very few methods for the simul-
aneous estimation of CFX and DLX in combination
ith other antibiotics in biological samples as single
rug candidates in biological fluids have been described.
he literature survey uncovered reports on analytical
ethods such as UV–VIS, HPLC, LC–MS, LC–MS–MS
nd HPTLC for the determination of CFX [3–16] and
LX [3,4,16–29] alone or in combination with other
ntibiotics (as formulations and in biological samples).
n addition, the methods that have been described are
ot very cost-effective in terms of solvent consump-
ion and total analysis run time; therefore, the present
tudy was conducted. The exhaustive literature survey
evealed that none of the most recognized pharma-
opoeias and journals include these drugs in combination
or the simultaneous determination of CFX and DLX,
nd information regarding the stability of the drugs is
ot available. Therefore, it seemed essential to develop
 liquid chromatographic procedure that serves as a reli-
ble, accurate and stability-indicating HPLC method for
he simultaneous estimation of CFX and DLX in tablet
osage form. The present investigation was conducted
ith the goal of establishing a simple, rapid, and robust
tability-indicating RP-HPLC method for the simulta-
eous estimation of CFX and DLX in bulk and in tablet
orm.
.  Experimental
.1.  Chemicals  and  reagents
All reagents and solvent were of analytical grade; they
ncluded hydrochloric acid, monobasic sodium phos-
hate, monobasic potassium phosphate, sodium acetate
rihydrate, orthophosphoric acid and methanol, which
ere purchased from Merck Ltd., Mumbai, India. High-
urity deionized water was obtained using a Millipore,
illi-Q (Bedford, MA, USA) purification system. Theefixime, dicloxacillin (Blok Pharma Pvt. Ltd, Kolha-
ur), acetonitrile (Merck Chemicals) and all the other
hemicals used were of analytical grade. Doubly distilled
ater was used for preparing the mobile phase solutions.Fig. 1. Chemical structure of (a) Cefixime (CFX) and (b) Dicloxacillin
(DLX).
The tablets containing cefixime and dicloxacillin (com-
mercial name: Hifen-LXX 200) were obtained from
a local market in Atpadi, Maharashtra (India). The
0.45–l m nylon filters were purchased from Advanced
Micro Devices Pvt. Ltd., Chandigarh, India.
2.2.  Instrumentation
A Cyberlab-chrom-HPLC V 4.0 isocratic high pres-
sure liquid chromatograph (Cyberlabs, USA) with an
LC-P-100 pump, an LC-UV 100 variable wavelength
programmable UV/Vis detector and Cyberstore version
4-0512-039 were used. Chromatographic separation was
performed by a reverse-phase Capcell Pak C18 DDS5
column (4.6 mm ×  250 mm with a particle size of 5 m).
2.3.  Chromatographic  conditions
The mobile phase, which consisted of 5 mM phos-
phate buffer (pH 5.4): acetonitrile:methanol (42:55:03,
v/v/v), was degassed and filtered using a Millipore vac-
uum filter system equipped with a 0.45 m membrane
filter. Chromatography was performed at an ambient
temperature by pumping the mobile phase at a flow rate
of 1.0 mL min−1. The column’s effluence was monitored
at 225 nm.
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2.4.  Preparation  of  the  stock  solution
Accurately weighed quantities of CFX and DLX
(10 mg) were transferred to a 10.0 ml volumetric flask.
Then, a small amount of the mobile phase was added
and the result was ultrasonicated for 5 min and diluted
up to the mark with the mobile phase to obtain a final
concentration of 1000 g mL−1.
2.5.  Preparation  of  the  standard  working  solution
From the CFX and DLX stock solutions, 1 ml was
transferred to a 10 ml volumetric flask by pipetting, and
the final volume was made up with the mobile phase to
obtain a final concentration of 100 g mL−1.
2.6.  Preparation  of  the  working  sample  solution
The powder from twenty tablets (Hifen-LXX 200),
each containing 200 mg CFX and 500 mg DLX, were
weighed. A quantity of powder that was equivalent to
10 mg CFX and 25 mg DLX was placed in each of several
10 mL volumetric flasks that contained approximately
5 mL of the mobile phase for analysis, and the result was
sonicated for 15 min. After sonication, the volume was
made up to the mark using the same solution to obtain the
sample stock solution of CFX (1000 g mL−1) and DLX
(2500 g mL−1). Then, the solution was filtered using a
0.45 m membrane filter. The filtrate (0.010 mL) was
quantitatively transferred to a 10 mL volumetric flask to
obtain final concentrations of 10 g mL−1 for CFX and
25 g mL−1 for DLX.
2.7.  Method  validation
The chromatographic conditions described in the
present manuscript were found to be appropriate for the
quantitative determination. After the analytical condi-
tions had been optimized, certain parameters such as
the linearity, precision, accuracy (recovery), selectivity,
and robustness were evaluated to validate the method
[30,31].
2.7.1. System  suitability  test
System suitability tests were performed in accordance
with USP 24/NF 19 to confirm that the reproducibility
of the equipment was adequate for the analysis [31]. The
test was performed before the analysis of each batch of
samples to ensure the reproducibility of the chromato-
graphic system. The criteria selected were based on the
actual performance of the method, as determined dur-
ing its validation. These parameters include the relativeniversity for Science 10 (2016) 734–744
standard deviation (%RSD) of the retention times, tailing
factor, theoretical plate and asymmetry for six repetitions
of the injection.
2.7.2. Linearity
The linearity was studied using six concentrations,
0.5, 1, 5, 10, 15, 20 and 25 g mL−1, of CFX and DLX.
The linearity experiment was performed six times to
ensure that the detector’s response was linear for various
drug concentrations (0.5–25 g mL−1). The working
standards were prepared by adding CFX and DLX
solutions with different concentrations to obtain concen-
trations in the required range; then, the solutions were
injected into the HPLC system. The calibration curves
were constructed by plotting the peak area versus the
concentrations of CFX and DLX, and the regression
equations were determined.
2.7.3.  Accuracy  (%  recovery)
The precision and accuracy of the HPLC method can
often be enhanced, which also corrects fluctuations in
the detector’s response. A study of the accuracy was
conducted using the standard addition method. The pre-
quantified sample solutions of CFX (2.00 g mL−1) and
DLX (5.00 g mL−1) were spiked with an extra 0, 50,
100, and 150% of the standard CFX and DLX solutions,
respectively. These mixtures were analyzed using the
developed method. The experiment was conducted six
times. The percentage recovery of the samples, %RSD
and the percentage were calculated for each concentra-
tion.
2.7.4. Precision
The intra-day and inter-day precision were esti-
mated for three different concentrations (0.5, 15 and
25 g mL−1) of CFX and DLX six times on each of three
days to obtain the relative standard deviation (%RSD).
2.7.5. The  LOD  and  the  LOQ
Several approaches for determining the detection
(LOD) and quantification (LOQ) limits are described in
the ICH guidelines. In this study, the LOD and the LOQ
were based on the standard deviation of the response and
the slope using the signal-to-noise ratio in accordance
with ICH guidelines [30].
2.7.6. Robustness
The robustness of the developed method was mea-sured to evaluate the influence of a small but deliberate
variation in the chromatographic conditions. The robust-
ness of the method was measured by changing the flow
rate (0.9 and 1.1 mL min−1) of the mobile phase, the pH
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oig. 2. A typical chromatogram of a tablet sample solution containing
0 g mL−1 of CFX and 25 g mL−1 of DLX.
5.3 and 5.5) of the phosphate buffer and the amount
41% and 43%) of the buffer in the mobile phase.
.7.7. Selectivity
The selectivity was verified by comparing the chro-
atograms obtained for the standard, the sample and the
orresponding placebo.
.8.  Forced  degradation
The International Conference on Harmonization
ICH) guideline entitled “Stability Testing of New Drug
ubstances and Products” requires that stress testing be
onducted to elucidate the inherent stability characteris-
ics of an active substance [30]. The aim of this work was
o study the stress degradation of CFX and DLX using
he proposed method [32,33].
.8.1. Hydrolytic  degradation  under  acidic
onditions
Using 20 g mL−1 and 50 g mL−1 stock solutions
f CFX and DLX, respectively, 5 mL of a stock solu-
ion and 1 mL of 0.1 N HCl were added to a 10 mL
olumetric flask. Then, the volumetric flask was kept
nder 60–70 ◦C reflux conditions for 4 h and neutral-
zed with 0.1 N NaOH and 10 mL of a diluent to obtain
0 g mL−1 and 25 g mL−1 concentrations of CFX and
LX, respectively. The solution was cooled to room tem-
erature, filtered using 0.45 m syringe filters and placed
n the vials of the HPLC system..8.2. Hydrolytic  degradation  under  alkaline
onditions
Using 20 g mL−1 and 50 g mL−1 stock solutions
f CFX and DLX, respectively, 5 mL of a stock solutionniversity for Science 10 (2016) 734–744 737
and 1 mL of 0.1 N NaOH were added to a 10 mL volu-
metric flask. Then, the volumetric flask was kept under
60–70 ◦C reflux conditions for 4 h and neutralized with
0.1 N HCl. Then, 10 mL of a diluent was added to obtain
10 g mL−1 and 25 g mL−1 concentrations of CFX and
DLX, respectively. The solution was cooled to room tem-
perature, filtered using 0.45 m syringe filters and placed
in the vials of the HPLC system.
2.8.3. Oxidative  degradation
Using 20 g mL−1 and 50 g mL−1 stock solutions
of CFX and DLX, respectively, 5 mL of a stock solu-
tion and 1 mL of 3% (w/v) of hydrogen peroxide were
added to a 10 mL volumetric flask. The volumetric flask
was then kept under 60–70 ◦C reflux conditions for 1 h,
and the volume was made up to the mark with dilu-
ents to obtain final CFX and DLX concentrations of
10 g mL−1 and 25 g mL−1, respectively. The solution
was cooled to room temperature, filtered using 0.45 m
syringe filters and placed in the vials of the HPLC sys-
tem.
2.8.4. Thermal  induced  degradation
Using 20 g mL−1 and 50 g mL−1 stock solutions
of CFX and DLX, respectively, 5 mL of a stock solu-
tion was added to a 10 mL volumetric flask. Then, the
volumetric flask was kept at 60–70 ◦C in a hot air oven
for 24 h, and the volume was made up to the mark with
diluents to obtain 10 g mL−1 and 25 g mL−1 concen-
trations of CFX and DLX, respectively. The solution
was cooled to room temperature, filtered using 0.45 m
syringe filters and placed in the vials of the HPLC sys-
tem.
2.8.5. Photo  degradation
Using 20 g mL−1 and 50 g mL−1 stock solutions
of CFX and DLX, respectively, 5 mL of a stock solution
was added to a 10 mL volumetric flask. The samples
were transferred to petri dishes and kept in a photo sta-
bility chamber (200 W h/m2 of UV light and 1.2 million
l ×  h of visible light) for 7 days. Then, the volumetric
flask was made up to the mark with diluents to obtain
10 g mL−1 and 25 g mL−1 concentrations of CFX and
DLX, respectively. The solution was cooled to room tem-
perature, filtered using 0.45 m syringe filters and placed
in the vials of the HPLC system.
3.  Results  and  discussionTo optimize the RP-HPLC parameters and reach
a good resolution and a peak shape for CFX and
DLX, several chromatographic conditions were tested.
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Table 1
System suitability test parameter for CFX and DLX having concentration 10 g mL−1 and 25 g mL−1.
Ob No. Retention time Tailing factor Theoretical plate Asymmetry
CFX DLX CFX DLX CFX DLX CFX DLX
1 2.84 3.96 0.5135 0.7752 5145 3987 0.7021 0.8821
2 2.84 3.94 0.5267 0.7241 5365 4012 0.6785 0.9235
3 2.85 3.95 0.5614 0.7485 5021 3745 0.7475 0.9465
4 2.83 3.92 0.5356 0.7075 5275 4085 0.6975 0.9748
5 2.83 3.95 0.5427 0.7012 5365 4785 0.7012 0.8685
6 2.86 3.94 0.5671 0.7475 5254 3985 0.7085 0.9765
Mean 2.84 3.94 0.5411 0.7340 5237.50 4099.83 0.7058 0.9286
S.D 0.01 0.01 0.0204 0.0281 133.88 354.74 0.0227 0.0459
%RSD 0.41 0.35 3.7779 3.8370 2.55 8.65 3.2274 4.9462
Table 2
Linear regression analysis of calibration curves (n = 6).
Drug Linearity range (g mL−1) Intercept Slope Correlation coefficient (r2) LOD (g mL−1) LOQ (g mL−1)
CFX 0.5–25 2502.67 24,235.52 0.9999 0.020 0.315
DLX 0.5–25 −1445.58 28,420.84 0.9999 0.018 0.205
Table 3
Accuracy (% Recovery) determined with developed method (n = 6).
Excess
drug added
to analyte
(%)
Theoretical
content
(g mL−1)
Concentration
found
(g mL−1)
(mean ± SD)
%
Recovery
(mean ± SD)
%RSD
CFX DLX CFX DLX CFX DLX CFX DLX
0 2 5 1.9456 ± 0.0355 5.0259 ± 0.0506 97.28 ± 1.7797 100.51 ± 1.0121 1.8294 1.0068
50 3 7.5 2.9790 ± 0.0138 7.4715 ± 0.0868 99.30 ± 0.4613 99.62 ± 1.1583 0.4645 1.6227
100 4 10 4.0185 ± 0.0453 9.9889 ± 0.0718 100.46 ± 1.1329 99.88 ± 0.7187 1.1277 0.7195
150 5 12.5 5.0240 ± 0.0521 12.4421 ± 0.0966 100.48 ± 1.0439 99.53 ± 0.7728 1.0389 0.7764
Table 4
Inter-day and intra-days precision of CFX and DLX standards.
Theoretical
concentration
(g mL−1)
CFX DLX
Intra-day
concentration
(Meana ± S.D)
Measured
RSD%
Inter-days
concentrationb
(Meana ± S.D)
Measured
RSD%
Intra-day
concentra-
tion
(Meana ± S.D)
Measured
RSD%
Inter-days
concentrationb
(Meana ± S.D)
Measured
RSD%
0.5 0.5058 ± 0.0101 2.0060 0.5100 ± 0.0101 1.3109 0.5089 ± 0.0093 1.8274 0.5130 ± 0.0145 2.8293
15 14.9971 ± 0.1219 0.8128 14.9823 ± 0.1456 0.3446 15.0663 ± 0.0964 0.6398 15.0390 ± 0.1361 0.9053
25 25.0151 ± 0.1163 0.4651 25.0496 ± 0.4670 0.2833 24.9988 ± 0.0769 0.3079 25.0830 ± 0.1377 0.5491
a Mean values represent six different CFX and DLX standards for each concentration.
b Inter-days reproducibility was determined from six different runs for three consecutive day.
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Table 5
Robustness study.
Variation Chromatographic parameter
Tailing factor Theoretical plate % Assay
CFX CLX CFX CLX CFX CLX
41% of phosphate buffer in mobile phase 0.5321 0.7275 5579.23 4398.35 98.36 99.65
43% of phosphate buffer in mobile phase 0.5685 0.7675 5654.44 4254.45 100.85 98.75
Flow rate at 0.9 mL min−1 0.6043 0.8012 5698.12 4365.45 101.85 101.52
Flow rate at 1.1 mL min−1 0.7950 0.9251 5495.45 4354.45 99.45 102.35
pH of mobile phase at 5.3 0.5245 0.6751 5698.56 4256.10 101.45 99.85
pH of mobile phase at 5.5 0.5565 0.7965 5675.52 4145.32 100.85 98.75
Table 6
% Degradation of CFX and DLX in different conditions.
Degradation condition Time (h) Area Conc. (g mL−1) % Potency % Degradation
CFX DLX CFX DLX CFX DLX CFX DLX
Acidic/0.1 N
HCl/60–70 ◦C/Reflux/4 h/Solution
0 h 253,052 713,425 9.9538 25.0138 99.53 100.05
4 h 225,587 689,554 8.8734 24.1768 88.73 96.70 10.80 3.34
Alkaline/0.1 N
NaOH/60–70 ◦C/Reflux/4 h/Solution
0 h 252,510 712,965 9.9325 24.9977 99.32 99.99
4 h 209,609 632,675 8.2449 22.1826 82.44 88.73 16.87 11.26
Oxidative/3%
H2O2/60–70 ◦C/Reflux/1 h/Solution
0 h 255,021 714,003 10.0312 25.0341 100.31 100.13
1 h 201,643 610,907 7.9316 21.4194 79.31 85.67 20.99 14.45
Thermal/60–70 ◦C/in hot air
oven/24 h/Solid
0 h 253,541 713,252 9.9730 25.0077 99.73 100.03
24 h 244,764 696,976 9.6278 24.4371 96.27 97.74 3.45 2.28
Photo/1.2 million lux h fluorescent
light/200 W/m2 of UV/7 days
0 h 254,001 713,220 9.9911 25.0066 99.91 100.02
7 days 235,521 679,564 9.2642 23.8266 92.64 95.30 7.26 4.72
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ieveral mobile phases of different compositions were
ested to find one that provided sufficient selectiv-
ty for the drugs. The phosphate buffer provided a
igher sensitivity and selectivity than other buffers did.
sing methanol and acetonitrile as organic components
esulted in higher sensitivity, but varying the amounts of
ethanol and acetonitrile in the mobile phase affected
he resolution and run time. Varying the pH of the
obile phase resulted in poor peak shapes; therefore, we
ntroduced orthophosphoric acid into the mobile phase
o adjust the pH of the buffer to 5.4. The optimized
obile phase consisted of 5 mM phosphate buffer (pH
.4): acetonitrile:methanol (42:55:03, v/v/v). The col-
mn’s effluence was monitored at 225 nm. The optimal
njection volume was 10 L. The column’s tempera-
ure was maintained at 25 ◦C (ambient). The Capcell
ak C18 DDS5 column (4.6 mm ×  250 mm with a par-
icle size of 5 m) was used in its isocratic mode
ith a flow rate of 1 mL min−1. Retention times ofpproximately 2.85 ±  0.06 and 3.98 ±  0.07 min were
onsistently observed for CFX and DLX, respectively,
n all the analytical runs (Fig. 2).3.1.  Validation  of  the  proposed  method
3.1.1.  System  suitability  test
The chromatographic systems used in this analysis
must conform to the system suitability limits before
sample analysis can commence [31]. The tailing fac-
tor (T), theoretical plate number (N), retention time (RT)
and asymmetry factor (As) for the principal peak and
its degradation product were evaluated using CFX and
DLX concentrations of 10 mg mL−1 and 25 mg mL−1,
respectively. Typically, at least two of these criteria
must be satisfied to demonstrate a system’s suitability
for the proposed method. Some of the tests were con-
ducted using fresh standard solutions that included drug
compounds. The tailing factors were 0.5411 ±  0.0204
for CFX and 0.7340 ±  0.0281 for DLX. The theoretical
plate numbers (N) were 5237.50 ±  133.8800 for CFX
and 4099.83 ±  354.7429 for DLX. The chromatographic
conditions described ensured the adequate retention
and asymmetry of the drug compounds. The retention
times of the drug CFX and DLX were 2.8416 ±  0.0116
and 3.9433 ±  0.0136 min, respectively. The asymmetry
aibah University for Science 10 (2016) 734–744
Fig. 3. A typical HPLC chromatogram of acid stressed sample of CFX740 S.D. Bhinge, S.M. Malipatil / Journal of T
factors were found to be 0.7058 ±  0.0227 for CFX
and 0.9286 ±  0.0459 for DLX. The variation in the
retention time for six replicate injections of the drug
compounds resulted in %RSDs of 0.4113% for CFX and
0.3464% for DLX. The results obtained from the system
suitability tests (Table 1) satisfied the USP and ICH stan-
dards [30,31].
3.1.2.  Speciﬁcity
There was no interference from impurities, excipients
or additives. The additives in the tablets were practically
insoluble in the mobile phase, and the active constituents
were soluble.
3.1.3.  Linearity
A linear correlation was obtained between the peak
area used and the absorbance Vs concentrations of CFX
and DLX; the calibration curves were linear for con-
centrations between 0.5 and 25 g mL−1. The linearity
of the calibration curves was validated by the values of
the regression correlation coefficients (r2). The correla-
tion coefficients were 0.9999 for CFX and 0.9999 for
DLX. The results of the linearity experiment are listed
in Table 2.
3.1.4. Accuracy  (%  recovery)
The accuracy experiments were conducted using
the standard addition method. The proposed method
afforded a recovery of 97.28–100.51% after the addi-
tional standard drug solution was spiked with the
previously analyzed test solutions. The recovery percent-
ages for CFX and DLX were in the ranges from 97.28
to 100.48% and from 99.53 to 100.51%, respectively.
The values of the recovery (%) and %RSD are shown
in Table 3; they express the accuracy of the proposed
method.
3.1.5. Precision
The intra-day precision of the method ranged from
0.3079 to 2.006%RSD for CFX and DLX. The inter-day
precision of the method was found to be between 0.2833
and 2.8293%RSD for CFX and DLX, which indicate
that the developed method is precise (Table 4). The low
values of the RSD (%) indicate that the proposed method
is repeatable.
3.1.6.  LOD  and  LOQ
The LODs for CFX and CLX were found to be
0.020 and 0.018 g mL−1, respectively, and the LOQs
for CFX and CLX were 0.315–0.205 g mL−1, respec-
tively (Table 2).(a) and DLX (b).
3.1.7.  Robustness
Deliberate changes in the method, i.e., changes in the
composition of the mobile phase, the flow rate and the pH
of the phosphate buffer, did not significantly affect the
peak tailings, the theoretical plates or the percent assays
of CFX and DLX. The results are shown in Table 5.
3.2.  Stability  indication
The ICH guideline entitled “Stability Testing of
Drug Substances and Products” requires that stress test-
ing be conducted to elucidate the inherent stability
characteristics of an active substance and to rapidly
identify differences that might result from changes in
the manufacturing process or the sample’s source [32].
Formulation drug products were exposed to thermal
stress, hydrolytic stress under acidic and basic condi-
tions, oxidative stress, and photolytic stress. An ideal
stability-indicating method is one that quantifies the
standard drug alone and also resolves its degradation
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Fig. 4. A typical HPLC chromatogram of alkali stressed sample of
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Fig. 5. A typical HPLC chromatogram of oxidative stressed sample of
FX (a) and DLX (b).
roducts. As described in Section 2, different types
f stress were used: boiling, acid, base hydrolysis,
xidation, and irradiation with UV light. During the
egradation study, CFX was degraded in comparison
o DLX under all stress conditions. Although unknown
egradant peaks were observed in the acid, base, per-
xide, photolytic and thermal study, no degradant peaks
ere reported in the retention time of CFX or DLX.
herefore, CFX and DLX are stable up to specified
eriod (4 h) when the proposed method is used, or they
re susceptible to acids, alkali, heat, hydrogen peroxide
nd photolytic stress.
.2.1.  Degradation  of  CFX  and  DLX  in  0.1  N  HCl
t 60–70 ◦C  for  4  h under  reﬂux  conditions
The results showed multiple peaks for the degra-
ation products. Major degradation peaks were found
t 0.95 and 2.03 min for CFX and at 5.83 min for
LX in both drug products and drug substances. CFXCFX (a) and DLX (b).
and DLX peaks were observed at retention times of
2.84 min and 3.96 min, respectively. The % drug degra-
dations observed were 10.80% and 3.34% for CFX and
DLX, respectively (Table 6). No degradant peaks were
reported in the retention time of CFX or DLX (Fig. 3a
and b).
3.2.2. Degradation  of  CFX  and  DLX  in  0.1  N  NaOH
at 70 ◦C  for  4  h  under  reﬂux  conditions
The results showed two peaks, at retention times
of 1.35 and 2.54 min, for CFX in both drug products
and drug substances. The % drug degradations observed
for CFX and DLX were 16.87% and 11.26%, respec-
tively (Table 6). This shows that DLX is much more
prone to alkaline hydrolysis than CFX, and significant
degradation of both drugs was observed. No degradant
peaks were reported in the retention time of CFX or DLX
(Fig. 4a and b).
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Fig. 6. A typical HPLC chromatogram of thermal stressed sample of Fig. 7. A typical HPLC chromatogram of photolytic stressed sample
CFX (a) and DLX (b).
3.2.3.  Oxidation  degradation  of  CFX  and  DLX  in
3% H2O2 at  70 ◦C  for  approximately  1 h  under
reﬂux conditions
The sample and drug substances were treated with a
3% solution of hydrogen peroxide and kept in a water
bath at 60–70 ◦C under reflux conditions for approxi-
mately 1 h. Major degradation peaks were found at 0.56
and 1.60 min for CFX in drug substances and drug prod-
ucts. The observed % degradations of CFX and DLX
were 20.99 and 14.45%, respectively (Table 6). There-
fore, note that CFX exhibited the maximum amount of
degradation under peroxide degradation conditions. No
degradant peaks were reported in the retention time of
CFX or DLX (Fig. 5a and b).
3.2.4. Thermal  degradation  of  CFX  and  DLX  at
60 ◦C  for  approximately  24  h
The thermal degradation of CFX and DLX at
60 ◦C for approximately 24 h in a hot air oven wasof CFX (a) and DLX (b).
studied. Degradation peaks were found at 0.88 and
2.05 min for CFX in drug products. The % degrada-
tions of CFX and DLX were found to be 3.45 and
2.28%, respectively (Table 6). No degradant peaks were
reported in the retention time of CFX or DLX (Fig. 6a
and b).
3.2.5.  Photolytic  degradation  of  CFX  and  DLX
The sample and drug substances were exposed to
the energy of a 1.2 million lux h fluorescent light and
to 200 W/m2 of UV light for approximately 7 days.
Minor degradation peaks were at 0.58 min and 2.50 min
for CFX and at 6.53 min for DLX in both drug sub-
stances and drug products. The % degradations of CFX
and DLX were found to be 7.26 and 4.72%, respectively
(Table 6). CFX showed the least degradation under pho-
tolytic conditions. No degradant peaks were reported in
the retention time of CFX or DLX (Fig. 7a and b).
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.  Conclusion
The proposed RP-HPLC method is accurate, precise,
apid, robust, sensitive and selective. The prescribed
ethod adapted the use of an economical and easily
vailable mobile phase, a UV detector, and easy extrac-
ion procedures. Washing the column with the same
obile phase made it an excellent method for the quan-
ification of CFX and DLX in bulk drugs and in their
harmaceutical dosage forms. A stability-indicating RP-
PLC method for the estimation of CFX and DLX in
heir solid dosage forms was established and validated in
ccordance with the ICH guidelines. The forced degrada-
ion experiment and the peak purity data confirmed that
here was no merging of the peaks of the active ingre-
ients with those of any other degradation products or
ther additives. The developed method can be used in
outine analyses of drugs in bulk and in different for-
ulations and could help in therapeutic drug monitoring
TDM) and bioavailability studies.
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